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Background/Aims: Vascular access dysfunction is an important cause of morbidity and mortality in hemodialysis (HD) 
patients. Recent studies have shown that a klotho gene mutation is related to endothelial dysfunction, thrombosis, and 
arteriosclerosis, which are regarded as causes of vascular access dysfunction. We investigated the relationship between 
the  klotho  G-395A  polymorphism  and  early  dysfunction  in  vascular  access  in  HD  patients.
Methods:  Patients  who  underwent  vascular  access  operations  between  1999  and  2002  were  enrolled  (n=126). 
Genotyping was performed by allelic discrimination using a 5’-nuclease polymerase chain reaction assay. Clinical data 
that could be relevant to access dysfunction were obtained from medical records. Early dysfunction of vascular access 
was  defined as  the  need  for any angioplastic  or surgical intervention  to  correct  or  replace  a  poorly  or  nonfunctioning 
vascular  access  within  1 year  and  at  least  8 weeks  after  initial  access  placement.
Results:  Of  t he 126 pat i ent s,  t he genot ype f r equency of  G- 395A was  72.2% for GG (n=91), 24.6% for GA (n=31), 
and 3.2% for AA (n=4), and the frequency of minor allele was 0.155. Clinical data were similar between the two groups, 
divided according to the status of the A allele. Early dysfunction occurred in 34 (27.0%) of patients, but it occurred at 
a  significantly  higher  rate  in  A  allele  carriers  (45.7%,  16/35)  than  in  noncarriers  (19.8%,  18/91;  p=0.003). 
  Conclusions: Our results suggest that the klotho G-395A polymorphism could be a risk factor for early dysfunction 
of  vascular  access  in  HD  patients.
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INTRODUCTION
 Vascular access dysfunction, causing considerable morbidity 
and  mortality,  is  one  of  the  most  important  complications  in 
hemodialysis  (HD)  patients
1-4).  In  addition,  this  dysfunction  is 
common; it occurs in up to 30% of patients in the early period 
following  access  placement  operations
4-7).  The  major  patho-
physiologic  mechanism  is  venous  thrombosis,  following  stenosis 
near the anastomosis site
5-7). Several studies have reported that 
vascular access dysfunction is related to clinical factors (diabetes, 
old  age),  biochemical  factors  (abnormalities  of  cytokines, 
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vascular  factors  (vessel  size,  decreased  blood  flow  rate,  intimal 
hyperplasia,  atherosclerosis)
8-12).  In  addition,  some  studies  have 
shown that point mutations in proteins involved in the coagulation 
system and proinflammatory cytokines associated with endothelial 
dysfunction and vessel wall proliferation are related to thrombosis 
and  atherosclerosis
9-12).
The overall biological effect of the klotho gene is suppression 
of  the  aging  process;  mice  that  over-express  the  klotho g e n e  
have an increased life span
13). Kuro-o et al.
14)  reported that in an 
experimental  mouse  model,  klotho  gene  defects  induced 
premature  aging  processes,  including  osteoporosis,  infertility, 
senile  atrophy  of  the  gonads,  thymus,  and  skin,  physical 
i n a c t i v i t y ,  a n d  p u l m o n a r y  e m p h y s e m a .  T h e y  a l s o  s u g g e s t e d  i t s  
involvement in progressive  vascular atherosclerosis  and vascular 
calcification
14). Other studies in humans have demonstrated that 
the functional variant of the klotho gene (KLVS) is associated with 
longevity  and  early-onset  occult  coronary  artery  diseases 
(CADs)
15,  16). This variant of the klotho gene has been shown to 
be  associated  with  high-density  lipoprotein  (HDL)  cholesterol, 
systolic blood pressure, and stroke, suggesting an association of 
this genetic variation with vascular atherosclerosis
15). In a Korean 
population,  Rhee  et  al
17)  showed  that  some  klotho g e n e  
polymorphisms  were  related  to  coronary  artery  disease  and 
hypertension. Kim et al
18) also reported that klotho gene polymor-
phisms were risk factors for ischemic stroke. Notably, the klotho 
g e n e  G - 3 9 5A  p ol y mo r p h i s m w a s  s h o w n  t o b e  r e l a t e d  t o t h e s e 
atherosclerotic diseases in both studies. The present study was 
conducted  to  investigate  the  relationship  between  the  klotho 
G-395A  polymorphism  and  early  vascular  access  dysfunction  in 
Korean  HD  patients.
MATERIALS AND METHODS
Study  subjects
Between January 1999 and December 2002, 126 consecutive 
patients who underwent vascular access creation surgery by an 
experienced  surgeon  at  our  hospital  were  placed  on  main-
tenance  HD  at  our  hospital  and  an  affiliated  clinic.  All  were 
enrolled in the study. Patients with a history of previous access 
failure,  those  who  had  any  problems  with  central  veins  on 
preoperative  venography,  and  those  who  had  access  failures 
w i t h i n  t h e  f i r s t  8  w e e k s  a f t e r  s u r g e r y  w e r e  e x c l u d e d .
This study was approved by the institutional ethics committee 
of our hospital. All participants provided written informed consent 
after  being  given  a  complete  description  of  the  study.
Clinical  assessment
Clinical  data  collected  from  medical  records  included  age, 
gender,  underlying  diseases,  vascular  disease,  number  of 
antihypertensive  drugs,  fasting  glucose  level,  HbA1c,  serum 
albumin,  total  cholesterol,  triglycerides,  HDL  cholesterol,  LDL 
cholesterol, serum calcium and phosphorus, intact PTH, and the 
type and location of vascular access. Mean serum levels at three 
time points (the time at which dysfunction was detected, the day 
of  the  operation,  and  2  months  before  surgery)  were  obtained 
from  the  laboratory  data.
Definition  of  early  dysfunction  of  vascular  access
Early  dysfunction  of  vascular  access  was  defined  as  a 
situation  requiring  any  angiographic  or  surgical  intervention  due 
to  malfunctioning  access  within  1  year  after  surgery.  Access 
failure  within  the  first  8  weeks  postsurgery  was  considered  a 
failure  of  the  surgery.
Genotyping  of  klotho  gene  polymorphisms  using  real-  time 
polymerase  chain  reaction  (PCR)
A  buffy  coat  preparation  was  obtained  from  blood  samples 
and refrigerated at -70℃. Genomic DNA was extracted using a 
Takara  DNA  Purification  kit  (Takara  Bio,  Shiga,  Japan). 
Genotyping of the G-395A polymorphism in exon 4 of the klotho 
gene was performed using an allelic discrimination assay. Briefly, 
a probe was annealed to its target sequence and the substrate 
generated  was  cleaved  using  the  5’-3’  nuclease  activity  of 
Taq  DNA  polymerase  (Takara  Bio)  as  it  extended  from  an 
upstream  primer  into  the  region  of  the  probe.  The  probe  was 
labeled  with  a  “reporter”  dye  at  its  5’-end  and  with  a 
“quencher”  dye  at  its  3’end.  When  intact,  the  proximity  of 
the  quencher  substantially  reduced  the  light  emitted  by  the 
reporter. The TaqMan probe (Takara Bio) is designed to anneal 
to  the  target  sequence  between  the  traditional  forward  and 
reverse  primers.  During  PCR,  Taq  DNA  polymerase,  with  its 
5’-3’  nuclease  activity,  catalyzes  primer  extension,  while  the 
fluorogenic TaqMan probe hybridizes to a specific sequence on 
the DNA template, where it encounters the oncoming Taq DNA 
polymerase from upstream. The exonuclease activity of the Taq 
DNA polymerase cleaves the probe, with the release of reporter 
dye,  resulting  in  an  increased  fluorescent  signal,  which  is 
detected by the instrument. The detector used in this experiment 
was  an  ABI  Prism  7200  sequence  detection  platform  (Perkin 
E l m e r  A p p l i e d  B i o s y s t e m s ,  F o s t e r  C i t y ,  C A ,  U S A ) .  
The  primers  and  probes  used  were  as  follows:
Forward  primer,  TAGGGCCCGGCAGGAT;
Reverse  primer,  CCTGGAGCGGCTTCGTC;
FAM-labeled  probe,  CAAGTCGGGGAAAG;  and
VIC-labeled  probe,  AGTCGGGAAAAGT.
The reaction conditions used for the Taq thermocycler were 2 
min at 50℃, 10 min at 95℃, 40 cycles for 15 s each, and then 
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Parameters Total  (n=126) GG  (n=91) GA+AA  (n=35) p
*
Age
Gender  (M:F)
Underlying  diseases
  D i a b e t e s  ( % )
  H y p e r t e n s i o n  ( % )
  G N  ( % )
  O t h e r s  ( % )
Vascular  diseases
  C A D  ( % )
  C V A  ( % )
  P A D  ( % )
N a t i v e  A V F  ( % )
    Radiocephalic  AVF  (%)
  B r a c h i o c e p h a l i c  A V F  ( % )
Systolic  BP  (mm  Hg)
Diastolic  BP  (mm  Hg)
Number  of  antihypertensives
Total  cholesterol  (mg/dL)
Triglyceride  (mg/dL)
HDL  cholesterol  (mg/dL)
LDL  cholesterol  (mg/dL)
Fasting  glucose  (mg/dL)
HbA1c  (%)
Serum  albumin  (g/dL)
Serum  calcium  (mg/dL)
Serum  phosphorous  (mg/dL)
I n t a c t  P T H  ( p g / m L )
59.61±11.60
1.17:1  (68:58)
68  (54.0)
38  (30.2)
6  (4.8)
14  (11.1)
10  (7.9)
3  (2.4)
1  (0.8)
108  (85.7)
96  (88.9)
12  (11.1%)
145.31±18.36
84.45±12.79
3.06±1.64
199.22±40.69
136.40±75.40
56.50±12.65
139.97±31.14
132.17±60.24
6.58±1.20
3.68±0.40
9.07±0.72
4.49±1.45
133.27±166.16
58.86±11.77
0.98:1  (45:46)
53  (58.2)
24  (26.4)
4  (4.4)
10  (11.0)
6  (6.6)
3  (3.3)
1  (1.1)
79  (86.8)
70  (88.6)
9  (11.4)
146.22±19.25
85.24±13.55
3.13±1.55
198.33±42.21
136.18±78.86
56.99±12.52
138.43±32.26
136.47±64.10
6.63±1.22
3.68±0.39
9.06±0.73
4.44±1.46
135.33±176.39
61.57±11.05
1.92:1  (23:12)
15  (42.9)
14  (40.0)
2  (5.7)
4  (11.4)
4  (11.4)
0  (0)
0  (0)
29  (82.9)
26  (89.7)
3  (10.3)
142.94±15.82
82.40±10.44
2.89±1.84
201.34±37.07
136.92±67.15
55.33±12.95
143.97±28.06
121.00±47.84
6.30±1.20
3.67±0.41
9.11±0.69
4.61±1.42
127.06±133.70
0.241
0.101
0.121
0.136
0.756
0.944
0.368
0.277
0.534
0.570
0.756
0.821
0.372
0.266
0.449
0.691
0.577
0.426
0.373
0.198
0.582
0.930
0.764
0.548
0.827
*Significantly  different  between  patients  with  GG  and  those  with  GA+AA,  as  measured  by  the  independent  samples  t-test  for 
continuous  variables  and  by  the  chi-square  test  for  dichotomous  variables.
AVF,  arteriovenous  fistula;  BP,  blood  pressure;  CAD,  coronary  arterial  disease;  CVA,  cerebrovascular  accident;  GN,  glomerulonephritis; 
HbA1c,  hemoglobin  A1c;  HDL,  high-density  lipoprotein;  LDL,  low-density  lipoprotein;  PAD,  peripheral  arterial  disease;  PTH,  parathyroid 
hormone.
Table  1.  Comparison  of  general  characteristics  according  to  G395A  polymorphism  genotypes
Statistical  analysis
All  statistical  analyses  were  performed  with  SPSS  for 
Windows  (version  10.0;  SPSS,  Chicago,  IL).  All  results  are 
expressed  as  means±standard  deviation  and  a  p v a l u e  l e s s  
than  0.05  was  deemed  to  be  statistically  significant.  We 
performed  the  chi-square  test  to  confirm  that  the  genetic 
frequency  of  the  klotho p o l y m o r p h i s m .  T h e  a l l e l e  f r e q u e n c y  o f  
the  klotho  polymorphism  was  consistent  with  Hardy-Weinberg 
equilibrium.  The  chisquare  test  and  the  t-test  were  used  to 
compare  clinical  characteristics  according  to  klotho  G-395A 
genotypes, the chi-square test was used to compare difference in 
the prevalence of early dysfunction of vascular access according to 
klotho  G395A  genotypes,  and  binary  logistic  regression  analysis 
was  performed  to  investigate  any  relationship  between  early 
access  dysfunction  and  the  klotho  G-395A  polymorphism,  with 
adjustments  for  age,  gender,  type  of  vascular  access,  and 
diabetes mellitus. Survival rates of patients with early dysfunction 
of  vascular  access  according  to  genotypes  are  expressed  as 
medians  and  ranges,  survival  curves  were  prepared  using  the 
Kaplan-Meier  method,  and  differences  in  the  survival  rate  were 
analyzed  using  the  log-rank  test. 
RESULTS
General  characteristics  of  the  study  subjects
In  total,  126  Korean  patients  were  included;  their  mean  age 
w a s  5 9 . 6 ± 1 1 . 6  y e a r s ,  a n d  t h e  r a t i o  o f  m e n  t o  w o m e n  w a s  
1.17:1.  The  most  common  cause  of  end-stage  renal  disease 
was  diabetes  (n=68,  54.0%).  Fourteen  patients  had  vascular 
diseases:  coronary  artery  diseases  (n=10,  7.9%),  cerebrovas-
cular diseases (n=3, 2.4%), and peripheral arterial diseases (n=1, 
0.8%).  A  native  arteriovenous  fistula  was  created  in  most 
patients (n=108, 85.7%); of them, it was created in the forearm 
with radiocephalic anastomosis in most cases (n=96, 88.9%). All 
arteriovenous  grafts  were  created  using  6-mm  diameter  PTEF 
grafts  on  the  forearm.  The  mean  systolic  and  diastolic  blood 
pressures  were  145.31±18.36  and  84.45±12.79 mm  Hg, The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 204
Genotype GG  (n=91) GA+AA  (n=35)
Without  early  dysfunction  (%)
W i t h  e a r l y  d y s f u n c t i o n  ( % )
7 3  ( 8 0 . 2 )                             1 9  ( 5 4 . 3 )
1 8  ( 1 9 . 8 )                             1 6  ( 4 5 . 7 )
The  chi-square  test  was  used  to  compare  the  frequency  of  early  dysfunction  of  vascular  access  according  to  the  different  genotypes.
*Significantly  different  between  genotypes. 
Table  2.  Relationship  between  klotho  genotype  and  early  access  dysfunction  (p=0.003
*)
Parameters Parameter  estimate χ
2 Odds  ratio CI  (Confidence  Interval)
Age
Gender
Genotype  type
Initial  access  type
DM
0.025
1.196
1.23
-0.977
0.765
0.212
0.016
0.011
0.113
0.103
1.025
3.306
3.331
0.376
2.149
0.986-1.067
1.250-8.743
1.316-8.431
0.112-1.262
0.856-5.392
DM,  diabetes  mellitus
Table  3.  Binary  logistic  regression  analysis  of  early  access  dysfunction
Figure 1. Kaplan-Meier survival curves of vascular access according to 
genotypes  (GG  vs.  GA+AA)  show  that  the  survival  rate  of  vascular 
access  of  A  allele  carriers  was  significantly  lower  than  that  of 
noncarriers  (p=0.001).
Continuous  line:  GA+AA  (A  allele  carrier),  Dashed  line:  GG  (noncarrier).
respectively.  The  number  of  antihypertensive  drugs  being  taken 
w a s  3 . 0 6 ± 1 . 6 4 .  T h e  r e s u l t s  o f  l a b o r a t o r y  t e s t s  a r e  s h o w n  i n  
Table  1.
Allele  frequencies  of  the  genotypes 
Of  the  126  subjects,  91  (72.2%)  had  the  GG  genotype,  31 
(24.6%) the GA genotype, and 4 (3.2%) the AA genotype (Table 
1).  The  allele  frequency  was  0.845  for  allele  G  and  0.155  for 
allele  A,  which  was  in  compliance  with  Hardy-Weinberg 
equilibrium  (p=0.310).
Comparison  of  biochemical  data  according  to  the  A  allele 
status 
According to the A allele status, patients were divided into A 
allele  carriers  (GA+AA)  and  noncarriers  (GG).  No  statistically 
significant differences in clinical and laboratory results were found 
b e t w e e n  t h e  g r o u p s  ( T a b l e  1 ) .
Early  dysfunction  of  vascular  access  according  to  genotype
Early  access  dysfunction  occurred  in  34  patients  (27.0%). 
According  to  the  genotypes,  this  dysfunction  developed  in  18 
(19.8%)  of  the  patients  with  the  GG  genotype,  13  (19.8%)  of 
those with GA, and 3 (75.0%) of those with AA. The rate of early 
vascular  dysfunction  was  higher  in  A  allele  carriers  than  in 
noncarriers (45.7% vs. 19.8%, p=0.003; Table 2). This difference 
was  statistically  significant  in  the  binary  logistic  regression 
analysis after adjusting for age, gender, type of vascular access, 
and  diabetes  mellitus  (p=0.011,  odds  ratio=3.331;  Table  3). 
Unexpectedly,  the  rate  of  early  dysfunction  was  higher  in  male 
patients  (p=0.016,  odds  ratio=3.306;  Table  3).
Comparison  of  survival  rates  according  to  genotype
The  median  survival  rate  of  patients  with  failed  vascular 
access  was  4.03  months  (range:  1.84-11.84  months).  The 
median  survival  rates  of  A  allele  carriers  and  noncarriers  were 
4.03  months  (range:  1.84-10.78)  and  4.65  months  (range: 
1.91-9.93),  respectively.  The  survival  rate  of  failed  vascular 
access  analyzed  by  the  log-rank  test  was  lower  in  A  allele 
carriers  than  in  noncarriers  (p=0.001;  Figure  1). 
DISCUSSION
The  results  of  this  study  indicated  that  the  klotho  G-395A 
polymorphism  was  related  to  early  vascular  access  dysfunction 
in  Korean  HD  patients.  Early  dysfunction  of  vascular  access 
o c c u r r e d  i n  2 7 . 0 %  o f  t h e  p a t i e n t s ;  d y s f u n c t i o n  w a s  m o r e  Youngsu  Kim,  et  al.  klotho  polymorphism  and  early  vascular  access  dysfunction 205
common  and  occurred  earlier  in  A  allele  carriers  than  in 
noncarriers. The A allele frequency of the G-395A polymorphism 
i n  t h e  p r o m o t e r  o f  t h e  klotho  gene  was  0.155,  approximately 
midway  between  the  values  quoted  from  the  Japanese  (0.143) 
and Korean literature (0.170). These values in Asian populations 
are lower than those reported in Caucasian populations (0.196)
17,
19).  Previous  genetic  studies  on  vascular  access  failure  have 
documented  that  several  polymorphisms  involved  in  the 
coagulation  system,  endothelial  dysfunction,  and  vessel  wall 
proliferation are related to thrombosis and endothelial dysfunction 
of  vascular  access
10, 12). 
Since  a  novel  mouse  mutant,  klotho,  was  discovered 
incidentally by Kuro-o et al.
14) many studies have been performed 
to  uncover  the  secret  of  the  aging  process  because  the  gene 
defect in mice leads to phenotypes resembling human premature 
aging  processes,  such  as  a  short  life  span,  growth  retardation, 
senile  atrophy  of  the  genitals,  thymus,  and  skin,  defective 
hearing,  osteoporosis,  and  pulmonary  emphysema.  Notably, 
mutant  mice  show  impressive  features  of  atherosclerosis, 
including  medial  calcification  and  intimal  hyperplasia  throughout 
the vasculature
14).  Additionally,  some  studies  have  reported  that 
this gene influences the development of atherosclerosis through 
decreased endothelial NO production in mutant mice or reduced 
expression  of  the  klotho  gene  in  the  kidney  in  hypertensive, 
nephrectomized,  and  OLETF  (Otsuka  Long-Evans  Tokushima 
Fatty) rats
20). Furthermore, Saito et al
21)  suggested that the klotho 
gene regulates endothelial function and atherosclerosis, based on 
the  finding  that  klotho  gene  transfer  increased  NO  production 
and  prevented  perivascular  fibrosis  in  OLETF  rats,  an 
experimental  animal  model  of  atherosclerosis.  Another  report 
noted  that  plasminogen  activator  inhibitor-1,  a  factor  for  the 
development  of  thrombosis,  is  highly  expressed  in  a 
klotho-deficient  mouse
22).
  Some  studies  in  humans  have 
demonstrated that a functional variant of the klotho gene, KL-VS, 
is  related  to  high-density  lipoprotein  (HDL)  cholesterol,  systolic 
blood pressure, longevity, coronary artery disease, and their risk 
factors
15, 16).  Based  on  these  results,  functional  defects  in  the 
klotho  gene  may  affect  vascular  access  dysfunction  caused  by 
thrombosis and stenosis. Kawano et al
19) showed that the G395A 
p o l y m o r p h i s m  i s  c o m m o n  a n d  h a s  f u n c t i o n a l  r e l e v a n c e  i n  a  
Japanese population.
  Additionally, two previous studies in Korean 
populations  have  suggested  that  this  polymorphism  can  affect 
vascular diseases
17, 18). In this study, the rate of early dysfunction 
of  vascular  access  was  higher  in  A  allele  carriers  than  in 
noncarriers (p=0.003; Table 2), and this difference was consistent 
with  that  of  other  important  variables  in  the  binary  logistic 
regression  analysis  (p=0.011,  odds  ratio=3.331;  Table  3).  This 
r e s u l t  i s  a n  i m p o r t a n t  f i n d i n g  i n  t h e  G - 3 9 5 A  p o l y m o r p h i s m ’ s  
involvement  in  vascular  disease.  Another  key  finding  is  that  A 
allele carriers suffered access dysfunction earlier than noncarriers. 
This  suggests  that  this  polymorphism  could  be  used  to  detect 
patients  with  a  higher  risk  of  early  dysfunction.  Further  studies 
are  warranted  on  this  point.
Failure of vascular access in HD patients is very common and 
clinically  important
1, 2).  Previous  studies  have  shown  that  early 
dysfunction  of  vascular  access  ranged  from  20%  to  30%, 
although  the  definition  of  ‘early’  varied  from  3  to  12  months 
after the operation
4-7). In this study, 34 patients (27.0%) suffered 
early  dysfunction  of  vascular  access,  defined  as  a  situation 
requiring  any  angiographic  or  surgical  intervention  for 
malfunctioning access within 1 year
10). The patients in this study 
were older (59.6 years old) than those in the two previous similar 
studies  (49.2  and  53.0  years  old)  in  Korea,  but  other  clinical 
characteristics were similar
6, 7). The proportion of males tended to 
be  higher  in  A  allele  carriers  than  in  noncarriers,  but  the 
difference  was  not  significant  (p=0.101;  Table  1).
While many studies
5-9) have reported no association between 
gender and vascular complications, some have stated that female 
gender  appears  to  be  a  risk  factor  for  early  failure
23-25).  In  this 
study, unexpectedly, early dysfunction was associated with male 
gender  (p=0.016,  odds  ratio=3.306;  Table  3).  Differences  in 
vessel diameter have been suggested to account for an increase 
in  access  complications  in  female  patients.  However,  as 
preoperative  measurements  of  vessel  diameter  were  made  by 
venography in all patients at our center, adverse effects of vessel 
diameter can be avoided. Thus, differences in access placement 
practice between the United States and Korea seem to limit the 
extent  to  which  results  can  be  generalized  for  the  Korean 
p o p u l a t i o n .  A  s e c o n d  e x p l a n a t i o n  f o r  o u r  f i n d i n g  i s  t h a t  m a l e  
patients had more A alleles, the most powerful risk factor in our 
study. Moreover, the effects of the klotho gene on osteoporosis
19), 
nonverbal  reasoning
26) a n d  c a r d i o e m b o l i c  s t r o k e s
18)  in  human 
diseases  have  been  suggested  to  be  altered  by  female 
hormones
27). However, these suggestions have not been further 
examined  or  confirmed.  Finally,  the  number  of  antihypertensive 
drugs being taken was higher in males than females (3.41±1.61 
vs.  2.62±1.54;  p=0.006),  although  the  differences  in  systolic 
(146.43±17.54  vs.  143.93±19.48 mm  Hg;  p=0.451)  and 
diastolic  (83.87±13.09  vs.  85.38±12.46 mm  Hg,  p=0.511) 
blood pressures according to gender were nonsignificant. These 
findings suggest that a greater atherosclerotic load may occur in 
the vasculature of male patients compared to females, although 
other specific tests for load were not performed. Additionally, no 
difference in clinical or laboratory results was found between the 
two  groups,  divided  according  to  the  presence  of  early  access 
dysfunction,  in  this  study.
The primary limitations of our study were its small sample size 
and  retrospective  nature.  The  small  sample  size  may  have 
contributed  to  the  difference  in  the  ratio  of  males  to  females 
between  A  allele  carriers  and  noncarriers  (1.92:1  vs.  0.98:1, The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 206
p= 0 . 1 0 1 ) ,  a l t h o u g h  t h e  s a m e  r a t i o  w a s  r e p o r t e d  i n  a  p r e v i o u s  
study  with  a  larger  sample  size
21).  The  retrospective  nature  of 
this study may have prevented the collection of important clinical 
data,  such  as  specific  tests  for  atherosclerotic  load,  showing 
vessel  wall  stiffness,  anatomical  changes  in  blood  flow,  and 
vessel  size,  several  biochemical  factors  (anticardiolipin  antibody, 
lipoprotein  (a),  plasminogen  activator  inhibitor,  monocyte 
chemoattractant-1),  and  history  of  smoking,  which  could  affect 
the  number  of  antihypertensive d r u g s  b e i n g  t a k e n .  F u t u r e  
prospective  studies  with  larger  sample  sizes  are  needed  to 
further evaluate the effect of klotho gene polymorphisms on early 
access  dysfunction.
I n  c o n c l u s i o n ,  t h e  G - 3 9 5 A  p o l y m o r p h i s m  i n  t h e  p r o m o t e r  
region  of  the  klotho  gene  may  be  associated  with  the  early 
dysfunction  of  vascular  access  in  HD  patients.  In  particular,  A 
allele carriers may encounter vascular access dysfunction earlier 
than noncarriers. Thi s study provides the basis for clarifyi ng the 
role of the klotho gene in the pathogenesis of vascular diseases.
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